Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of “Moderate Buy” from Analysts

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has been given an average rating of “Moderate Buy” by the six ratings firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $7.25.

MIST has been the topic of several recent research reports. Wells Fargo & Company reduced their price target on Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a research report on Thursday, May 14th. Raymond James Financial initiated coverage on Milestone Pharmaceuticals in a research report on Friday, April 10th. They set a “strong-buy” rating and a $6.00 price target on the stock. Zacks Research lowered Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, May 15th. Finally, Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th.

Insider Activity

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 36,500 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $2.26, for a total value of $82,490.00. Following the transaction, the chief executive officer directly owned 446,244 shares of the company’s stock, valued at $1,008,511.44. This represents a 7.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of institutional investors have recently made changes to their positions in MIST. Propel Bio Management LLC raised its position in shares of Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after purchasing an additional 3,333,333 shares in the last quarter. Orbimed Advisors LLC acquired a new position in shares of Milestone Pharmaceuticals in the 3rd quarter valued at approximately $6,444,000. Marshall Wace LLP raised its position in shares of Milestone Pharmaceuticals by 289.8% in the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock valued at $3,347,000 after purchasing an additional 1,231,793 shares in the last quarter. Pathstone Holdings LLC acquired a new position in shares of Milestone Pharmaceuticals in the 3rd quarter valued at approximately $2,000,000. Finally, Boxer Capital Management LLC acquired a new position in shares of Milestone Pharmaceuticals in the 3rd quarter valued at approximately $1,333,000. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Stock Performance

Milestone Pharmaceuticals stock opened at $1.27 on Friday. The stock’s 50 day moving average price is $1.65 and its 200 day moving average price is $1.84. The firm has a market capitalization of $158.12 million, a PE ratio of -1.87 and a beta of 0.95. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.09 and a current ratio of 9.18. Milestone Pharmaceuticals has a one year low of $1.00 and a one year high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.26). The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $30.12 million. As a group, sell-side analysts expect that Milestone Pharmaceuticals will post -0.97 EPS for the current fiscal year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.